A Pediatric Research paper from Wolff and Koutroulis mapped serum immune biomarkers that correlate with disease severity and recovery trajectories in Multisystem Inflammatory Syndrome in Children (MIS‑C). The study identified specific cytokine and immune‑activation signatures that differentiated acute hyperinflammation from convalescence and suggested markers that could monitor therapeutic response. Authors highlighted implications for clinical management and trial design, proposing that biomarker panels help triage patients, tailor immunomodulatory therapy, and provide objective endpoints for interventional studies. Pediatric intensivists and sponsors running MIS‑C trials may integrate these markers into enrollment or stratification algorithms.